Sale!

Cisplatin 10 ML · Vial / Bottle

Cisplat 10 Mg/10 Ml Injection

Rx (Prescription Medicine)

Original price was: USD $ 19.70.Current price is: USD $ 15.76.

You save USD $ 3.94 (20%)

USD $ 1.58 per injection

Upload prescription Ask about this medicine
  • Dispatched from licensed pharmacy partners
  • Tracked worldwide shipping
  • Secure payment
Category:

Key facts

Active ingredient
Cisplatin
Strength
10 ML, 10 Mg
Form
Injection
Drug class
Generic
Brand
Cisplat
Manufacturer
Biochem Pharmaceutical
Pack sizes
10 ML

Description

Cisplat 10 Mg/10 Ml Injection – Cisplatin Chemotherapy

Cisplat 10 Mg/10 Ml Injection contains Cisplatin 10 mg in 10 ml (1 mg/ml) as a sterile aqueous solution for intravenous infusion. Cisplatin is a platinum-based alkylating-like chemotherapy agent and one of the most widely used drugs in oncology. It was among the first metal-based anticancer compounds approved for clinical use and remains a cornerstone of treatment protocols for a wide range of solid tumours. Cisplatin is used in curative, adjuvant, and palliative settings, often in combination with other cytotoxic agents. It is administered only under the supervision of experienced oncologists in clinical settings equipped to manage its significant toxicity profile, particularly nephrotoxicity and emetogenic potential.

Composition

Each vial (10 ml) contains:

  • Cisplatin IP – 10 mg (1 mg/ml)
  • Excipients: Sodium Chloride, Hydrochloric Acid (for pH adjustment), Water for Injection

How Cisplatin Works

Cisplatin (cis-diamminedichloroplatinum II) exerts its cytotoxic effects by forming DNA adducts that interfere with DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells.

After intravenous administration, cisplatin enters cells via active transport and passive diffusion. Inside the cell, one or both chloride ligands are displaced by water molecules in a process of aquation, forming highly reactive aquated platinum species. These reactive species then form covalent bonds with the N7 position of purine bases in DNA — primarily guanine — creating intrastrand crosslinks (most commonly Pt-GG intrastrand adducts) and interstrand crosslinks. These cisplatin-DNA adducts distort the double helix, block DNA replication and RNA transcription, and trigger DNA damage response pathways.

When the DNA damage exceeds the cell’s repair capacity, apoptosis is initiated via both the intrinsic (mitochondrial) and extrinsic (death receptor) pathways. Cancer cells undergoing rapid division are more susceptible to this damage than most normal cells, though rapidly dividing normal tissues (e.g. renal tubular cells, haematopoietic cells, gastrointestinal epithelium) are also affected — explaining cisplatin’s major toxicities.

Uses of Cisplat 10 Mg/10 Ml Injection

  • Testicular germ cell tumours: Cisplatin is a cornerstone of BEP (Bleomycin, Etoposide, Cisplatin) and other regimens; it has transformed testicular cancer from a frequently fatal disease to a highly curable one.
  • Ovarian cancer: Used in combination with paclitaxel or carboplatin as first-line treatment for advanced ovarian carcinoma.
  • Bladder cancer: Part of MVAC (Methotrexate, Vinblastine, Adriamycin, Cisplatin) and GC (Gemcitabine-Cisplatin) regimens for transitional cell carcinoma.
  • Non-small cell lung cancer (NSCLC): Used in doublet chemotherapy regimens as standard of care in non-targeted therapy settings.
  • Head and neck squamous cell carcinoma: Combined with radiation therapy (chemoradiation) or as systemic chemotherapy in advanced disease.
  • Cervical cancer: Combined with radiation in concurrent chemoradiotherapy, improving locoregional control and overall survival.
  • Gastric and oesophageal cancer: Part of combination regimens including ECF (Epirubicin, Cisplatin, Fluorouracil).
  • Mesothelioma: Used in combination with pemetrexed as standard first-line treatment.

Dosage and Administration

Cisplatin dosing is individualised by oncologists based on body surface area (BSA), treatment protocol, organ function (particularly renal function), and prior therapies:

  • Typical doses range from 50 to 100 mg/m² administered by IV infusion every 3 to 4 weeks, depending on the regimen.
  • Adequate pre-hydration with intravenous saline (1 to 2 litres before and after cisplatin infusion) is mandatory to protect against nephrotoxicity.
  • Prophylactic antiemetic therapy (5-HT3 antagonists such as ondansetron, NK1 receptor antagonists such as aprepitant, and corticosteroids) must be given before infusion — cisplatin is classified as highly emetogenic.
  • Cisplatin must never be administered without confirmed adequate renal function; creatinine clearance should be ≥60 ml/min before each cycle.
  • Electrolyte levels (magnesium, potassium, sodium) must be monitored and corrected as cisplatin causes urinary wasting of electrolytes.
  • Administered only in hospital or specialist oncology centre settings by trained healthcare professionals.

Side Effects

  • Nephrotoxicity: The most dose-limiting toxicity. Cumulative damage to renal tubular cells can cause acute kidney injury; prevented by aggressive hydration and dose spacing.
  • Nausea and vomiting: Cisplatin is one of the most highly emetogenic chemotherapy agents; prophylactic antiemetics are essential.
  • Ototoxicity: Irreversible high-frequency hearing loss and tinnitus, particularly at high cumulative doses; audiometric monitoring is recommended.
  • Peripheral neuropathy: Sensory neuropathy (numbness, tingling) in hands and feet; may be cumulative and partially irreversible.
  • Myelosuppression: Leucopenia, thrombocytopenia, and anaemia; nadir typically around 14–21 days after each cycle.
  • Electrolyte disturbances: Hypomagnesaemia, hypokalaemia, hypocalcaemia due to renal wasting; may require supplementation.
  • Alopecia: Variable; less common than with anthracyclines.

Precautions and Warnings

  • Renal function monitoring: Measure serum creatinine and creatinine clearance before each cycle; withhold if renal function is significantly impaired.
  • Hearing assessment: Perform audiometric testing before and during treatment, especially in children and elderly patients.
  • Neurotoxicity monitoring: Assess for peripheral neuropathy before each cycle; cumulative dose should be tracked.
  • Myelosuppression: Full blood counts must be checked before each infusion; delay or dose-reduce if counts are inadequate.
  • Pregnancy and fertility: Cisplatin is teratogenic and may cause permanent infertility; discuss fertility preservation before initiating therapy.
  • Patients should report any ringing in the ears, sudden hearing changes, or reduced urine output immediately.

Drug Interactions

  • Aminoglycoside antibiotics (gentamicin, amikacin): Additive nephrotoxicity and ototoxicity; avoid concurrent use or monitor very closely.
  • Loop diuretics (furosemide): Additive ototoxic potential; use with caution.
  • Other nephrotoxic agents: NSAIDs, vancomycin — additive kidney injury risk; avoid or monitor carefully.
  • Live vaccines: Avoid during and for several months after cisplatin therapy due to immunosuppression.

Contraindications

  • Severe renal impairment (creatinine clearance <60 ml/min)
  • Existing significant hearing impairment
  • Severe myelosuppression
  • Known hypersensitivity to cisplatin or other platinum-containing compounds
  • Pregnancy — cisplatin is a known teratogen

Storage Instructions

Store at room temperature (15°C to 25°C). Protect from light. Do not refrigerate or freeze as precipitation may occur. Prepared infusion solutions should be used within the timeframe specified in institutional protocols. Keep out of reach of children and handle only by trained oncology personnel.

Related Products

References

  • National Cancer Institute. Cisplatin. NCI Drug Dictionary. cancer.gov
  • MedlinePlus. Cisplatin Injection. U.S. National Library of Medicine. medlineplus.gov
  • National Center for Biotechnology Information. Cisplatin – Compound Summary. PubChem. pubchem.ncbi.nlm.nih.gov

Additional information

Brand Name

Molecule

Strength

10 ML, 10 Mg

Medicine Form

Injection

Packaging Type

Vial / Bottle

Pack Quantity

10 ML

Country Of Origin

India

Medicine Type

Generic

Rx Status

Rx (Prescription Medicine)

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Same molecule & strength

Other brands of Cisplatin 10 ML — the same active ingredient at the same strength, from a different manufacturer.

On this page
  1. Key facts
  2. Description
  3. Additional information
  4. Reviews (0)
  5. Same molecule

Content integrity

Medically reviewed by

Renu Meena, B.Pharm (RSPC Reg. No. 55661)

Registered Pharmacist

Renu Meena is a registered pharmacist (Rajasthan State Pharmacy Council, Reg. No. 55661) with a Bachelor of Pharmacy (B.Pharm) from Rajasthan University of Health Sciences (RUHS), Jaipur. She reviews IndogenMed medicine pages for dosing, safety and interaction accuracy against official prescribing information. With 4+ years of experience across clinical pharmacy and medical content, her work is shaped by pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11 and safety reporting requirements.

Last reviewed 20/11/2026

Shipping to your country

Options
Shipping
Free over
USD $ 20,550.00